Novel Lipoprotein(a) Lowering Drug Pelacarsen Did Not Reduce Major Cardiovascular Events in Landmark Trial

A significant clinical trial led by Cleveland Clinic found that while the drug pelacarsen effectively lowered lipoprotein(a) (Lp(a)), a known risk factor for heart disease, it did not reduce major adverse cardiovascular events after nearly five years of follow-up. The Phase 3 Lp(a)HORIZON trial, presented at the American Heart Association's Scientific Sessions 2026 and simultaneously published in the New England Journal of Medicine, involved patients with existing heart disease already on standard treatments. The primary endpoint, a composite of heart-related death, heart attack, stroke, or urgent heart procedure, occurred in similar proportions in both the pelacarsen and placebo groups. The drug was associated with mild side effects and rare allergic reactions.

Context

Lipoprotein(a) is recognized as a significant risk factor for cardiovascular disease. Previous studies suggested that lowering Lp(a) could reduce heart disease risk, prompting the development of pelacarsen. The Lp(a)HORIZON trial enrolled patients with existing heart conditions who were already receiving standard care, making it a critical test for the drug's effectiveness.

Why it matters

The findings from the Lp(a)HORIZON trial highlight the complexities of treating cardiovascular risk factors. Despite lowering lipoprotein(a), pelacarsen did not lead to a reduction in major cardiovascular events, raising questions about the efficacy of targeting this specific biomarker. This outcome may influence future research and treatment strategies for heart disease.

Implications

The trial results may lead to a reevaluation of the role of lipoprotein(a) in cardiovascular risk management. Patients with high Lp(a) levels may need to continue relying on existing treatments rather than new therapies. Additionally, healthcare providers may need to adjust their treatment plans and expectations for patients with elevated Lp(a).

What to watch

Researchers and healthcare professionals will likely analyze the trial results to understand the implications for future treatments targeting lipoprotein(a). Ongoing discussions at medical conferences may focus on alternative strategies for managing cardiovascular risk. The pharmaceutical industry may also reassess the development of similar drugs based on these findings.